Transposagen, Inc. Licenses Broad Institute CRISPR/Cas9 Technology
December 11, 2015 09:00 ET
|
Transposagen Biopharmaceuticals, Inc.
LEXINGTON, Ky., Dec. 11, 2015 (GLOBE NEWSWIRE) -- Transposagen, Inc. today announced that it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual...
Transposagen Wins Prestigious Tibbetts Award for Development of Genome Engineering Technology
June 16, 2015 14:00 ET
|
Transposagen Biopharmaceuticals, Inc.
LEXINGTON, Ky., June 16, 2015 (GLOBE NEWSWIRE) -- Transposagen Biopharmaceuticals, Inc. (“Transposagen”), a privately-held biotechnology company, has accepted the highly prestigious 2015 Tibbetts...
Aragen Bioscience, Inc. and Transposagen Biopharmaceuticals, Inc. Partner to Launch FUT8 Knockout CHO DG44 Cell Line Development Services
June 16, 2015 11:00 ET
|
Transposagen Biopharmaceuticals, Inc.
LEXINGTON, Ky., June 16, 2015 (GLOBE NEWSWIRE) -- Aragen Bioscience, Inc. (“Aragen Bioscience”), in partnership with Transposagen Biopharmaceuticals, Inc. (“Transposagen), has developed a FUT8...
Transposagen announces partnering model for its exclusive patents covering rat models of oncology, autoimmune and inflammatory diseases and issuance of OncoRat(TM) registered trademark
April 20, 2015 04:00 ET
|
Transposagen Biopharmaceuticals, Inc.
Lexington, KY, Apr. 20, 2015 (GLOBE NEWSWIRE) -- Transposagen, a world leader in genome engineering technologies and services, announced the registration of its trademark OncoRat™ by the USPTO, for...
トランスポサジェンが、OncoRat™の腫瘍疾患、自己免疫疾患、炎症性疾患用のラットモデルの独占的特許に対する提携モデル、および登録商標としての登録を発表
April 19, 2015 21:00 ET
|
Transposagen Biopharmaceuticals, Inc.
Lexington, KY, Apr. 20, 2015 (GLOBE NEWSWIRE) --...
Transposagen announces partnering model for its exclusive patents covering rat models of oncology, autoimmune and inflammatory diseases and issuance of OncoRat(TM) registered trademark
April 19, 2015 21:00 ET
|
Transposagen Biopharmaceuticals, Inc.
Lexington, KY, Apr. 19, 2015 (GLOBE NEWSWIRE) -- Transposagen, a world leader in genome engineering technologies and services, announced the registration of its trademark OncoRat™ by the USPTO, for...
Transposagen announces partnering model for its exclusive patents covering rat models of oncology, autoimmune and inflammatory diseases and issuance of OncoRat™ registered trademark
April 16, 2015 13:00 ET
|
Transposagen Biopharmaceuticals, Inc.
Lexington, KY, April 16, 2015 (GLOBE NEWSWIRE) -- Transposagen, a world leader in genome engineering technologies and services, announced the registration of its trademark OncoRat™ by the...
Stemgent, a ReproCELL Group Company and Transposagen Biopharmaceuticals Enter Into a Service Partnership Agreement Providing Genetically Engineered Stem Cells
CAMBRIDGE, Mass. and LEXINGTON, Ky., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Stemgent, Inc., A ReproCELL Group Company (Cambridge, Massachusetts, USA) and Transposagen Biopharmaceuticals Inc. (Lexington,...
Transposagen Biopharmaceuticals Enters Into Research Collaboration and Worldwide License Agreement With Janssen for Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Therapies
November 24, 2014 12:00 ET
|
Transposagen Biopharmaceuticals, Inc.
LEXINGTON, Ky., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Transposagen Biopharmaceuticals, Inc., (Transposagen) a private biotechnology company headquartered in Lexington, KY, today announced they have...
Transposagen's Footprint-Free(TM) Gene Editing System Corrects Beta-Thalassemia Disease Mutation in Human iPS Cells
August 08, 2014 12:26 ET
|
Transposagen Biopharmaceuticals, Inc.
LEXINGTON, Ky., Aug. 8, 2014 (GLOBE NEWSWIRE) -- In the latest demonstration of Transposagen's Footprint-Free™ Gene Editing System, published this week in Genome Research, scientists from the...